What Flen Health Pharma does

Flen Health Pharma is a privately-held, family-owned Belgian-Luxembourgish biopharmaceutical company founded in 2000 by pharmacist Philippe Sollie. The company develops and commercializes proprietary wound and skin healing medical devices, with a portfolio centered on enzyme-based biopharmaceutical technology. Core products include Flaminal Hydro and Flaminal Forte (antimicrobial enzyme alginogels for acute and chronic wounds), Flamigel (hydro-active colloid gel with arginine for superficial wounds), Flamigel RT (radiotherapy skin protection), Extracalm (anti-itch gel spray), and Flamirins (isotonic wound cleanser). The company is advancing VES Gel, a patented recombinant enzyme complex for chronic diabetic foot ulcers, which is currently in FDA registration with clinical trials planned for 2026.

The company's technology platform combines absorbent alginate matrices with antimicrobial enzyme systems (glucose oxidase, lactoperoxidase, and guaiacol) to destroy microbes without developing resistance, a key differentiator versus conventional antimicrobials. Flen Health operates through seven wholly-owned affiliate offices across Belgium, Luxembourg, Netherlands, Germany, UK, Ireland, and Italy, with a US entity in development, distributing products in over 40 countries. Revenue is generated through direct field sales to healthcare professionals (wound care specialists, tissue viability nurses, radiotherapists, dermatologists), hospital procurement, pharmacy retail channels, and export distribution partnerships. The company maintains EN ISO 13485:2016 certification and CE marking for its products.

Flen Health is led by the Sollie family, with founder Philippe Sollie as President of the Board and his son Georges Sollie as CEO. The company has 110+ employees, approximately 10% dedicated to R&D, and has secured €7.1 million in external R&D grants over five years. It is recognized as a market leader in wound care and skin healing in the UK and Belgium, supported by 150+ case studies and 50+ scientific publications. The company achieved a 10% CAGR on net revenues over the 2020-2023 period.

Name

Flen Health Pharma

Legal name

Flen Health

Website

https://flenhealth.com

Company type

Private

Founded year

2000

Operating status

Operating

Short description

Flen Health Pharma is a privately-held Belgian-Luxembourgish biopharmaceutical company founded in 2000 that develops and commercializes proprietary enzyme-based wound and skin healing medical devices, including Flaminal, Flamigel, and Flamigel RT, distributed across 40+ countries through a seven-affiliate European network and a US entity in development.

Ownership category

akta.pro rank

Product category

Wound Care Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industries

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Wound Care & Diabetic Foot Infection (HLAKAGAK)

Keywords

• Wound care medical devices
• Antimicrobial enzyme dressings
• Skin healing products
• Biopharmaceutical wound therapy
• Radiotherapy skin care

Headquarters

HQ city

Kontich

HQ country

Belgium

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Medical Device Product Sales: Revenue generated from selling proprietary wound care and skin healing medical devices including Flaminal®, Flamigel®, Flamigel® RT, Extracalm®, and Flamirins® through affiliate offices and distribution networks across 40+ countries.
2. Biopharmaceutical Pipeline: Future revenue stream from VES Gel biopharmaceutical product currently in FDA registration process for US market entry, targeting chronic diabetic foot ulcers with recombinant enzyme technology.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

Flen Health Pharma develops, manufactures (via outsourced production) and distributes a proprietary portfolio of CE-marked wound and skin healing medical devices, including Flaminal® enzyme alginogels, Flamigel® hydro-active colloid gels, Flamigel® RT for radiotherapy skin care, Extracalm® anti-itch spray, and Flamirins® wound cleanser. The company also develops biopharmaceutical therapies, including a VES Gel recombinant enzyme complex for chronic diabetic foot ulcers currently in FDA registration, sold through wholly-owned European affiliates and a global distribution network reaching 40+ countries.

Product overview

Flen Health Pharma offers a portfolio of innovative wound and skin healing products designed for healthcare professionals and patients. The product portfolio includes Flaminal® Hydro/Forte (enzyme alginogel for acute and chronic wounds with antimicrobial properties), Flamigel® (hydro-active colloid gel for superficial wounds and burns), Flamigel® RT (specialized gel for radiotherapy-induced skin reactions), Extracalm® (anti-itch spray for irritated skin), and Flamirins® (wound cleanser). The company employs a biotechnological approach combining absorbent alginate technology with antimicrobial enzyme systems to create optimal wound healing environments.

Differentiator

Problem solved

Functional benefit

Products and services

• Flaminal Hydro Primary wound dressing for acute and chronic wounds with lower alginate content, designed for slightly to moderately exuding wounds. Contains the proprietary antimicrobial enzyme system for infection protection.
• Flaminal Forte Primary wound dressing for acute and chronic wounds with higher alginate content, designed for moderately to highly exuding wounds. Features absorbent alginate and the antimicrobial enzyme system.
• Flamigel Versatile hydro-active colloid gel with arginine for superficial wounds, minor wounds and first-degree burns. Accelerates wound healing up to 40% and reduces risk of scarring.
• Flamigel RT Hydro-active colloid gel for skin protection during radiotherapy. Delays onset and reduces incidence of radiotherapy-induced moist desquamation, supporting uninterrupted cancer treatment.
• Extracalm Anti-itch gel spray for itchy, painful, red or irritated skin. Provides immediate itch relief lasting over 140 minutes without cortisone, using silicone film technology for moisture balance and skin protection.
• Flamirins Isotonic buffered wound cleanser for mechanical wound cleansing. Creates low pH environment with polysorbate and citric acid to reduce bacterial growth and risk of infection.
• Flamigel Repair + Protect Handgel Hand care gel for skin repair and protection, extending the Flamigel consumer line into hand skincare.

Quantifiable outcome

• Accelerates wound healing up to 40% compared to standard treatment
• +5 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

20 partnerships are on record, tiered core and minor.

• Flanders.bio ClustercoreStrategic or Co-development PartnerStrategic partnership with Flanders.bio Cluster enabling innovation through portfolio of activities and programs supporting biotech and health technology development.
• Luxembourgish HealthTech Cluster (Luxinnovation)coreStrategic or Co-development PartnerPartnership managed by Luxinnovation supporting development of sustainable and trusted services and products aimed for the European healthcare market in digital health, medical devices, and neurology.
• Fit 4 Start ProgramminorStrategic or Co-development PartnerAcceleration programme managed by Luxinnovation dedicated to high potential start-ups. Flen Health supports new ideas and development potential through this youth development initiative.
• Leg ClubminorGTM or Marketing PartnerPartnership supporting wound care community and patient organization initiatives.
• Radiotherapy UKminorGTM or Marketing PartnerPartnership supporting radiotherapy patient care and education initiatives.
• Society of Tissue ViabilityminorGTM or Marketing PartnerPartnership supporting tissue viability education and best practices in wound care.
• JWC AwardsminorGTM or Marketing PartnerPartnership and sponsorship supporting wound care awards and recognition programs.
• Legs MatterminorGTM or Marketing PartnerPartnership supporting wound care awareness and patient education initiatives.
• European Wound Management Association (EWMA)coreStrategic or Co-development PartnerCollaboration includes sponsorship of Antimicrobial Stewardship Programme 2020 and active conference participation for advancing wound care practices.
• DEBRA (EB World Congress 2020)minorStrategic or Co-development PartnerCollaboration initiated for EB World Congress 2020 supporting epidermolysis bullosa patient community.
• ELA Luxembourg asblminorGTM or Marketing PartnerPartnership supporting leukodystrophy patient organization initiatives.
• Cure EB UKminorGTM or Marketing PartnerPartnership supporting epidermolysis bullosa research and patient care.
• LuxinnovationcoreStrategic or Co-development PartnerPartnership for innovation support, youth development programs, and health tech cluster management in Luxembourg.
• European American Chamber of CommerceminorGTM or Marketing PartnerPartnership supporting cross-border business development and networking opportunities.
• BemedtechminorGTM or Marketing PartnerPartnership with Belgian medical technologies association for industry collaboration.
• NefemedminorGTM or Marketing PartnerPartnership with Dutch medical technology federation for industry collaboration.
• Initiative Chronische Wunden (ICW)minorGTM or Marketing PartnerPartnership supporting chronic wound initiative and education in Germany.
• SDMA (Surgical Dressing Manufacturers Association) UKminorOthersAssociation membership for UK surgical dressing manufacturers industry engagement.
• Medical Technologies BelgiumminorOthersAssociation membership for Belgian medical technologies industry collaboration.
• Koen NaertminorStrategic or Co-development PartnerPartnership with Belgian athlete Koen Naert for Kenya Project supporting wound care in developing regions.

Scale indicators12 records

Recent moves12 records

Expansion highlights6 records

Broad incumbents

• Solventum (formerly 3M Health Care): Multinational medtech spun out of 3M with a large wound care and surgical solutions portfolio (Tegaderm, V.A.C. negative pressure therapy). Competes broadly with Flen Health across advanced wound care and skin protection categories.
• Smith+Nephew: Large multinational medtech with a substantial Advanced Wound Management division (ALLEVYN, PICO, ACTICOAT). Competes with Flen Health in burn, chronic wound, and surgical site care, but operates at much greater scale and across orthopedics and sports medicine as well.
• Hartmann Group: German medical products company with a Wound Management division spanning traditional dressings, advanced wound care, and compression therapy. Comparable to Flen Health in European wound care market presence and product breadth.
• Mölnlycke Health Care: Swedish wound care and surgical solutions leader (Mepilex, Mepitel, Avance negative pressure wound therapy). Strong incumbent in European markets where Flen Health operates, with comparable focus on foam and antimicrobial dressings for chronic and surgical wounds.
• Coloplast: Danish specialist in wound care (Biatain, Comfeel) alongside ostomy and continence. Closely comparable to Flen Health given overlapping wound dressing portfolio and direct sales models into hospitals and home care across Europe.

Emerging players

• Integra LifeSciences: US-listed specialty medical technology company with a wound care and regenerative tissue portfolio (Integra Dermal Regeneration Template, PriMatrix). Comparable to Flen Health's regenerative/biologic wound healing direction.
• MiMedx: US-based regenerative wound care company (EpiFix, AmnioFix) using placental tissue allografts. Comparable to Flen Health's biologic wound healing approach (recombinant enzymes vs. tissue grafts), targeting similar chronic wound and surgical recovery indications.

Direct peers

• Organogenesis: US-listed regenerative medicine company with Apligraf and Dermagraft skin substitutes for chronic wounds including diabetic foot ulcers. Directly comparable to Flen Health's VES Gel pipeline direction (biologic/regenerative wound therapies) and similar focus on diabetic foot ulcers.
• ConvaTec: Global wound care specialist with AQUACEL hydrofiber dressings and a portfolio spanning advanced wound care, ostomy, and continence. Directly comparable to Flen Health in wound care category focus, hospital channel sales model, and emphasis on antimicrobial and moisture-management technologies.
• Urgo Medical: French wound care specialist (UrgoClean, UrgoStart, Urgocell) with strong European footprint and emphasis on chronic wound healing. Direct competitor to Flen Health in UK, Belgium, and broader European hospital and community wound care channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Flen Health Pharma